Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lilly 1st Quarter Profits Down 5%

By Drug Discovery Trends Editor | April 19, 2010

INDIANAPOLIS (AP) – Health care reform charges helped chop Eli Lilly and Co.’s first-quarter profit by 5 percent, offsetting strong sales growth from some of its top-selling drugs.

The Indianapolis drugmaker said Monday it took a one-time charge of $85 million in the three months that ended March 31 due to its retiree prescription drug coverage, and it expects Medicaid-related rebates to shrink revenue by $350 million to $400 million this year.

As a result, Lilly reduced its 2010 adjusted earnings guidance to between $4.40 and $4.55 per share. The company said late last year it expected a profit of between $4.65 and $4.85 per share for 2010.

Analysts polled by Thomson Reuters expect, on average, earnings of $4.73 per share for 2010.

For the first quarter, Lilly said it earned $1.25 billion, or $1.13 per share. That’s down from the $1.31 billion, or $1.20 per share, last year.

Excluding charges, the adjusted profit was $1.18 per share.

Revenue rose 9 percent to $5.49 billion.

Analyst polled by Thomson Reuters expected, on average, a profit of $1.10 per share on revenue of $5.54 billion. Wall Street analysts typically exclude one-time charges or items, and Lilly spokesman Mark Taylor said they did not account for the impact of health care reform.

Sales for Lilly’s best-selling drug, the anti-psychotic Zyprexa, rose 8 percent to $1.2 billion, and sales of the cancer drug Alimta soared 57 percent to $527 million.

In contrast, the company’s newest drug, the blood thinner Effient, brought in only $8.8 million in the quarter. Lilly developed Effient with Japanese drugmaker Daiichi Sankyo Co.

Lilly’s research and development expenses rose 10 percent to $1.04 billion in the quarter mainly due to costs tied to late-stage drug trials. Lilly drugs in late-stage testing include a couple potential Alzheimer’s disease treatments.

Lilly said it took a charge of 8 cents per share in the quarter due to its retiree prescription drug coverage and the health care reform law passed last month by Congress. Several major corporations have already reported similar charges.

Under the new law, businesses will be prohibited starting in 2011 from writing off a federal subsidy that covers part of the cost of retiree prescription drug coverage. The government provides the subsidies so companies will continue offering coverage to retirees, which keeps them off government-funded Medicare Part D.

Lilly also took a charge of 4 cents per share in the quarter due to an increase in the rebate Lilly provides the government for drugs covered by Medicaid, the state-federal program that offers coverage to the elderly and disabled.

Lilly anticipates that the rebate increase will reduce earnings by 27 cents per share in 2010.

Shares of the company slipped 2.7 percent in premarket trading to $35.55 from Friday’s close of $36.54.

Date: April 19, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE